Literature DB >> 26595876

Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma are highly dependent on oxidative phosphorylation.

Katrin Birkenmeier1, Stefan Dröse2,3, Ilka Wittig3, Ria Winkelmann1, Viktoria Käfer1, Claudia Döring1, Sylvia Hartmann1, Tina Wenz4, Andreas S Reichert5, Ulrich Brandt6,7, Martin-Leo Hansmann1.   

Abstract

The metabolic properties of lymphomas derived from germinal center (GC) B cells have important implications for therapeutic strategies. In this study, we have compared metabolic features of Hodgkin-Reed-Sternberg (HRS) cells, the tumor cells of classical Hodgkin's lymphoma (cHL), one of the most frequent (post-)GC-derived B-cell lymphomas, with their normal GC B cell counterparts. We found that the ratio of oxidative to nonoxidative energy conversion was clearly shifted toward oxidative phosphorylation (OXPHOS)-linked ATP synthesis in HRS cells as compared to GC B cells. Mitochondrial mass, the expression of numerous key proteins of oxidative metabolism and markers of mitochondrial biogenesis were markedly upregulated in cHL cell lines and in primary cHL cases. NFkappaB promoted this shift to OXPHOS. Functional analysis indicated that both cell growth and viability of HRS cells depended on OXPHOS. The high rates of OXPHOS correlated with an almost complete lack of lactate production in HRS cells not observed in other GC B-cell lymphoma cell lines. Overall, we conclude that OXPHOS dominates energy conversion in HRS cells, while nonoxidative ATP production plays a subordinate role. Our results suggest that OXPHOS could be a new therapeutic target and may provide an avenue toward new treatment strategies in cHL.
© 2015 UICC.

Entities:  

Keywords:  classical Hodgkin lymphoma; energy metabolism; oxidative phosphorylation

Mesh:

Year:  2016        PMID: 26595876     DOI: 10.1002/ijc.29934

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  17 in total

1.  The second genome: Effects of the mitochondrial genome on cancer progression.

Authors:  Adam D Scheid; Thomas C Beadnell; Danny R Welch
Journal:  Adv Cancer Res       Date:  2019-02-27       Impact factor: 6.242

2.  A Bak-dependent mitochondrial amplification step contributes to Smac mimetic/glucocorticoid-induced necroptosis.

Authors:  Katharina Rohde; Lara Kleinesudeik; Stefanie Roesler; Oliver Löwe; Juliana Heidler; Katrin Schröder; Ilka Wittig; Stefan Dröse; Simone Fulda
Journal:  Cell Death Differ       Date:  2016-11-11       Impact factor: 15.828

Review 3.  Metabolic targeting of malignant tumors: a need for systemic approach.

Authors:  Aggelos T Margetis
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-04       Impact factor: 4.322

4.  Discovery and Lead Optimization of Benzene-1,4-disulfonamides as Oxidative Phosphorylation Inhibitors.

Authors:  Ding Xue; Yibin Xu; Armita Kyani; Joyeeta Roy; Lipeng Dai; Duxin Sun; Nouri Neamati
Journal:  J Med Chem       Date:  2022-01-04       Impact factor: 8.039

5.  Long noncoding RNA Hoxb3os is dysregulated in autosomal dominant polycystic kidney disease and regulates mTOR signaling.

Authors:  Karam Aboudehen; Shayan Farahani; Mohammed Kanchwala; Siu Chiu Chan; Svetlana Avdulov; Alan Mickelson; Dayeon Lee; Micah D Gearhart; Vishal Patel; Chao Xing; Peter Igarashi
Journal:  J Biol Chem       Date:  2018-05-01       Impact factor: 5.157

6.  Cooperative STAT/NF-κB signaling regulates lymphoma metabolic reprogramming and aberrant GOT2 expression.

Authors:  Maren Feist; Philipp Schwarzfischer; Paul Heinrich; Xueni Sun; Judith Kemper; Frederike von Bonin; Paula Perez-Rubio; Franziska Taruttis; Thorsten Rehberg; Katja Dettmer; Wolfram Gronwald; Jörg Reinders; Julia C Engelmann; Jan Dudek; Wolfram Klapper; Lorenz Trümper; Rainer Spang; Peter J Oefner; Dieter Kube
Journal:  Nat Commun       Date:  2018-04-17       Impact factor: 14.919

7.  Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma.

Authors:  Shahrzad Jalali; Tammy Price-Troska; Cole Bothun; Jose Villasboas; Hyo-Jin Kim; Zhi-Zhang Yang; Anne J Novak; Haidong Dong; Stephen M Ansell
Journal:  Blood Cancer J       Date:  2019-02-19       Impact factor: 11.037

Review 8.  NAD- and NADPH-Contributing Enzymes as Therapeutic Targets in Cancer: An Overview.

Authors:  Alvinsyah Adhityo Pramono; Gulam M Rather; Herry Herman; Keri Lestari; Joseph R Bertino
Journal:  Biomolecules       Date:  2020-02-26

9.  Mitochondrial Protein UQCRC1 is Oncogenic and a Potential Therapeutic Target for Pancreatic Cancer.

Authors:  Qing Wang; Mengge Li; Yu Gan; Shuheng Jiang; Jie Qiao; Wei Zhang; Yingchao Fan; Yuling Shen; Yanfang Song; Zihong Meng; Ming Yao; Jianren Gu; Zhigang Zhang; Hong Tu
Journal:  Theranostics       Date:  2020-01-12       Impact factor: 11.556

Review 10.  Why All the Fuss about Oxidative Phosphorylation (OXPHOS)?

Authors:  Yibin Xu; Ding Xue; Armand Bankhead; Nouri Neamati
Journal:  J Med Chem       Date:  2020-10-26       Impact factor: 8.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.